NEUROD1

Across TCGA pan-cancer cohorts, NEUROD1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NEUROD1 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher NEUROD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEUROD1 expression acts as an unfavorable survival marker.

BRCA, UCS, and PRAD are the cancer types where NEUROD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.027	0.907	<.001	16	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NEUROD1–BRCA (OS)

Open the BRCA breakdown →